NCT00545948 - Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Vinorelbine followed by Cisplatin

Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).

DRUG

Pemetrexed followed by Cisplatin

Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)

Trial Locations (13)

23970

Community Memorial Health Center, South Hill

27536

Maria Parham Hospital, Henderson

27577

Johnston Memorial Hospital Authority, Smithfield

27609

Duke Raleigh Hospital, Raleigh

27710

Duke University Medical Center, Durham

28204

Presbyterian HealthCare, Charlotte

28352

Scotland HealthCare System (Scotland Memorial Hospital), Laurinburg

28358

Southeastern Regional Medical Center, Gibson Cancer Center, Lumberton

28472

Columbus County Hospital, Whiteville

29572

Coastal Cancer Center, Myrtle Beach

29902

Beaufort Memorial Hospital, Beaufort

33401

Palm Beach Cancer Institute, West Palm Beach

60637

University of Chicago Medical Center, Chicago